ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 425

Efficacy, Pharmacokinetics, and Safety of Different Doses of Methotrexate in Combination With Adalimumab: Results From the Concerto Trial

Gerd Burmester1, Alan J. Kivitz2, Hartmut Kupper3, Udayasankar Arulmani4, Stefan Florentinus5, Sandra Goss4, Suchitrita S. Rathmann4 and Roy Fleischmann6, 1Charité - Universitätsmedizin Berlin, Berlin, Germany, 2Altoona Center for Clinical Research, Duncansville, PA, 3AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 4AbbVie Inc., North Chicago, IL, 5AbbVie, Rungis, France, 6University of Texas Southwestern Medical Center, Dallas, TX

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Adalimumab, methotrexate (MTX) and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy I

Session Type: Abstract Submissions (ACR)

Background/Purpose:  Anti-TNF plus methotrexate (MTX) is more effective than either as monotherapy. Thus far, no controlled data are available on the benefit:risk of different doses of MTX in combination with anti-TNF. The purpose of this study was to determine the effect of MTX dose in combination with adalimumab (ADA) on efficacy, pharmacokinetics, and safety in patients (pts) with early rheumatoid arthritis (RA).

Methods:  CONCERTO was a 26-week (wk), double-blind, parallel-arm trial in MTX and biologic-naive pts with active RA [DAS28(CRP) ≥3.2; CRP ≥1.5 mg/dL or ESR ≥28 mm/hr; ≥1 erosion or RF+ or ACPA+] of <1 year duration. Pts were randomized 1:1:1:1 to wkly oral MTX (2.5, 5, 10, or 20 mg) and received open-label (OL) ADA 40 mg every other wk (eow). Pts in the 20 mg arm began 10 mg and escalated 2.5 mg eow to 20 mg. The primary endpoint was the achievement of low disease activity [LDA, defined as DAS28(CRP) <3.2] at wk 26. Secondary endpoints included DAS28(CRP) (<2.6), ACR50/70/90, SDAI (≤3.3)/CDAI (≤2.8) remission, radiographic nonprogression (ΔmTSS ≤0.5), and ΔHAQ-DI ≤-0.22 at wk 26. Dose-response was assessed via Cochran-Armitage linear trend test. Non-responder imputation was used for missing data. Serum samples for pharmacokinetics were collected prior to baseline and at all study visits. Safety was assessed in terms of adverse events (AEs) for all pts who received ≥1 dose of study drug.

Results:  Of the 395 randomized pts, 358 (83, 93, 93, and 89 from the 2.5, 5, 10, and 20 mg arms, respectively) completed 26 wks. At wk 26, there was a statistically significant trend in the proportion of pts achieving DAS28(CRP) <3.2 with increasing dose of MTX in combination with OL ADA (Table). Significant trends were noted as early as wk 12 and sustained through wk 26. Similar results were observed for ACR50/70/90 and DAS28(CRP) < 2.6, SDAI/CDAI remission. Numerically increasing trends were also apparent in the proportions achieving radiographic nonprogression and ΔHAQ-DI ≤-0.22 at wk 26. Clinical and radiographic outcomes generally appeared comparable between the 10 and 20 mg arms. ADA serum concentrations were similar in the 10 and 20 mg MTX arms, with slightly lower mean ADA serum concentrations in the 2.5 and 5 mg arms. AEs were consistent with the known profile of anti-TNF and were generally consistent between arms, occurring most frequently in the 20 mg arm.

 

Parametera

2.5 mg MTX + OL ADA

5 mg MTX + OL ADA

10 mg MTX + OL ADA

20 mg MTX + OL ADA

P value

DAS28(CRP) <3.2, n/N (%)

42/98 (43)

44/100 (44)

56/99 (57)

59/98 (60)

.005

DAS28(CRP) <2.6, n/N (%)

27/98 (28)

32/100 (32)

37/99 (37)

44/98 (45)

.008

SDAI ≤3.3, n/N (%)

11/98 (11)

22/100 (22)

28/99 (28)

29/98 (30)

.005

CDAI ≤2.8, n/N (%)

12/98 (12)

22/100 (22)

29/99 (29)

27/98 (28)

.02

ACR50/70/90, %

46/24/7

51/34/10

54/41/17

62/46/16

.02/.003/.04

ΔmTSS ≤0.5, n/N (%)

63/98 (64)

72/100 (72)

76/99 (77)

76/98 (78)

.06

ΔHAQ-DI ≤-0.22, n/N (%)

67/98 (68)

70/100 (70)

73/99 (74)

76/98 (78)

.12

aNon-responder imputation.

Conclusion: MTX and biologic-naïve pts with early RA demonstrated robust and dose-dependent clinical responses with increasing doses of MTX in combination with OL ADA through 26 wks. Interestingly, clinical responses and ADA serum concentrations generally appeared similar between the 10 and 20 mg MTX arms.


Disclosure:

G. Burmester,

AbbVie Inc., BMS, Merck, Roche, Pfizer, and UCB,

2,

AbbVie Inc., BMS, Merck, Roche, Pfizer, and UCB,

5,

AbbVie Inc., BMS, Merck, Roche, Pfizer, and UCB,

8;

A. J. Kivitz,

AbbVie Inc., Pfizer, Genentech, UCB, Amgen, Celgene, BMS, Astra-Zeneca, and Janssen,

2,

Genentech, UCB, and BMS,

5,

BMS,

8;

H. Kupper,

AbbVie,

3,

AbbVie,

1;

U. Arulmani,

AbbVie,

1,

AbbVie,

3;

S. Florentinus,

AbbVie,

1,

AbbVie,

3;

S. Goss,

AbbVie,

1,

AbbVie,

3;

S. S. Rathmann,

AbbVie,

1,

AbbVie,

3;

R. Fleischmann,

AbbVie Inc., Pfizer, Merck, Roche, UCB, Celgene, Amgen, Astra-Zeneca, BMS, Janssen, Lilly, and Novartis,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-pharmacokinetics-and-safety-of-different-doses-of-methotrexate-in-combination-with-adalimumab-results-from-the-concerto-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology